Stay updated on Daratumumab in Waldenström Macroglobulinemia Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in Waldenström Macroglobulinemia Clinical Trial page.

Latest updates to the Daratumumab in Waldenström Macroglobulinemia Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedWaldenström macroglobulinemia is now listed as a condition on the page, and a Resources section has been added with a link to the Genetic and Rare Diseases Information Center.SummaryDifference0.2%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedRevision: v3.5.0 added and v3.4.3 removed; this appears to be a backend/UI update with no visible changes to the study details.SummaryDifference0.1%

- Check35 days agoChange DetectedThe page now displays Revision: v3.4.3, replacing Revision: v3.4.2.SummaryDifference0.1%

- Check64 days agoChange DetectedRevision: v3.4.2 was added. The lapse-in-funding notice and the earlier Revision: v3.4.1 entry were removed from the page.SummaryDifference0.4%

- Check71 days agoChange DetectedA site-wide notice about a lapse in government funding stating that information may not be up to date has been added, and the page revision indicator updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check78 days agoChange DetectedAdded a glossary toggle and standardized capitalization for several labels (Last Update Submitted that Met QC Criteria; No FEAR Act Data). The revision also updates the version to v3.4.0.SummaryDifference0.2%

Stay in the know with updates to Daratumumab in Waldenström Macroglobulinemia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in Waldenström Macroglobulinemia Clinical Trial page.